MGF

Synthetic 24-residue IGF-1Ec E-domain research peptide

≥ 99.0% · target, verify batch COACAS 77591-33-4RUO

Research statusPreclinical and mechanistically disputed; no established administered-human PK, safety or efficacy for the synthetic 24-mer.

Supplied formUnmodified linear 24-mer; termini and stabilization state confirmed per lot

Lead time14–21 days

MGF — Lot-specific lyophilized research peptide, commonly white to off-white; appearance is not an identity or sterility test

MGF — Lot-specific lyophilized research peptide, commonly white to off-white; appearance is not an identity or sterility test · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research applications include testing the proposed activity of the isolated E-domain sequence, comparing positive and negative myoblast findings, evaluating sequence or stabilization effects, and distinguishing IGF-1Ec transcript biology from mature IGF-1 signaling
These are research questions, not established muscle-repair or anti-ageing benefits.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 77591-33-4
Formula: C₁₂₁H₁₉₄N₄₀O₄₀ (unmodified ²⁴-mer with free termini; confirm supplied form on the batch COA)
Molecular weight: Approximately 2849.08 g/mol
Appearance: Lot-specific lyophilized research peptide, commonly white to off-white; appearance is not an identity or sterility test
Purity: ≥ 99.0% · target, verify batch COA
Storage: Follow the released-lot label and stability statement. Keep lyophilized material sealed and protected from moisture; qualify reconstituted concentration, solvent, pH, container, temperature and hold time. Avoid repeated freeze-thaw unless supported by lot-specific data.
MOQ: On request
Lead time: 14–21 days

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about MGF

This product is a synthetic 24-residue peptide corresponding to the unique C-terminal region of the human IGF-1Ec E domain. The term MGF is also used for the load-responsive IGF-1Ec transcript or propeptide. Peer-reviewed literature has not established that an identical free 24-mer is cleaved and released endogenously, so transcript expression and effects of an added synthetic peptide must be described separately.

IGF-1 splice-transcript research; synthetic E-domain peptide activity assays; myoblast and progenitor-cell models; structure-activity or stabilization studies; analytical differentiation of unmodified and PEGylated material.

Mechanism context

The question the literature is testing

Some studies report synthetic MGF-24aa-E effects in cell or animal models and propose signaling distinct from canonical IGF-1R. Other well-controlled work found no apparent myoblast or primary muscle-stem-cell activity. The receptor, endogenous processing and physiological relevance of the free 24-mer remain unresolved.

Evidence map

Research routes and exposure context

Evidence tierMixed evidence context

Research areaGrowth-hormone axis research

Routes reported in sources

No administration route applies

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Research Use Only; not an approved finished drug and not for human or veterinary use
Human safety is not established
WADA lists mechano growth factors in S2.3, prohibited at all times for athletes subject to the Code
Handle according to the SDS and institutional risk assessment.

Interactions reported in the literature

For experiments, control mature IGF-1, serum proteins, peptide concentration, modification state, cell source and assay timing
No clinical stack, insulin, GH-axis or other peptide-combination guidance is provided.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

MGF factory batch COAs

MGF 2 mg Factory batch COA protected preview

MGF2 mg · WHJLP-MGF2-260508-B

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require exact sequence and termini, modification status, RP-HPLC purity with method, intact mass, LC-MS/MS sequence confirmation where available, peptide content, counterion, water and residual solvents
Appearance or clear reconstitution cannot prove identity, activity, sterility or human suitability.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

MGF-2MG2 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released-lot label and stability statement. Keep lyophilized material sealed and protected from moisture; qualify reconstituted concentration, solvent, pH, container, temperature and hold time. Avoid repeated freeze-thaw unless supported by lot-specific data.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Core evidence includes PMID 20130113, 16024511, 19567392, 17581790, 21354439, 24253050, 24146828 and 23125840. Anti-doping status is verified against WADA S2.3. Positive and negative experimental findings must be interpreted together.

01
Mechanical Signals, IGF-I Gene Splicing, and Muscle Adaptation
Physiology (Bethesda) [American Physiological Society] · 2005 · peer-reviewed review article (foundational)
Open source
02
Expression of IGF-1 Isoforms after Exercise-induced Muscle Damage in Humans: Characterization of the MGF E Peptide Actions In Vitro
In Vivo · 2009 · peer-reviewed original research (human + in vitro)
Open source
03
Mechano-growth Factor Reduces Loss of Cardiac Function in Acute Myocardial Infarction
Heart, Lung and Circulation · 2008 · peer-reviewed original research (large-animal preclinical, sheep model)
Open source
04
Mechano Growth Factor E Peptide (MGF-E), Derived from an Isoform of IGF-1, Activates Human Muscle Progenitor Cells and Induces an Increase in Their Fusion Potential at Different Ages
Mechanisms of Ageing and Development · 2011 · peer-reviewed original research (human primary cell culture)
Open source
05
Mechano-growth Factor Peptide, the COOH Terminus of Unprocessed Insulin-like Growth Factor 1, Has No Apparent Effect on Myoblasts or Primary Muscle Stem Cells
American Journal of Physiology-Endocrinology and Metabolism · 2014 · peer-reviewed original research (contradictory/refutation study)
Open source
06
Insulin-Like Growth Factor I (IGF-1) Ec/Mechano Growth Factor – A Splice Variant of IGF-1 within the Growth Plate
PLoS One · 2013 · peer-reviewed original research (piglet growth plate model)
Open source
07
Mechano-Growth Factor: An Important Cog or a Loose Screw in the Repair Machinery?
Frontiers in Endocrinology · 2012 · peer-reviewed review/opinion article
Open source
08
The Prohibited List (2026) — S2.3 Growth Factors and Growth Factor Modulators
World Anti-Doping Agency (official regulatory body) · 2026 · regulatory/anti-doping body official document
Open source

Product FAQ

Questions buyers ask about MGF

What does “MGF” identify on this page?+

Here it identifies a synthetic 24-residue peptide, YQPPSTNKNTKSQRRKGSTFEEHK, corresponding to the unique C-terminal region of the human IGF-1Ec E domain. In biology papers, MGF can instead mean the IGF-1Ec transcript or full propeptide. Mature 70-residue IGF-1 is shared by the isoforms, and IGF-1 LR3 is an engineered receptor agonist. These materials and evidence types are not interchangeable.

Has the same free 24-residue peptide been proven to exist endogenously?+

Not conclusively. A peer-reviewed minireview found no demonstrated processing step that releases the proposed 24-mer from pro-IGF-1Ec. Studies of IGF-1Ec mRNA therefore show splice-variant expression, not necessarily production of a free MGF-24aa-E peptide. Likewise, effects after adding a synthetic peptide establish only that intervention in that model.

Ready for review

Request a usable quote

Include fill, quantity, target purity/content, required methods, destination and timing.

B2B response target: 24 hours
Latest lot requested separately
Cold-chain priced when needed

Research Use Only. Human-use requests are not accepted.

Recent activity window

Recent confirmed orders including MGF

Recent Confirmed Orders4 · Last 30 daysView all

United Kingdom550 mg2026-08-28

Tirzepatide 40 mg · Retatrutide 5 mg · MGF 2 mg · DSIP 2 mg · PEG-MGF 2 mg · BPC-157 2 mg

Ukraine3.9 g2026-08-18

GHK-Cu 100 mg · MGF 2 mg · LL-37 5 mg · PEG-MGF 2 mg · Sterile Water 3 mL

United States590 mg2026-08-12

GHK-Cu 50 mg · Retatrutide 5 mg · MGF 2 mg · CJC-1295 without DAC 2 mg

Australia2 g2026-08-05

Tirzepatide 100 mg · CJC-1295 + Ipamorelin 10 mg · ACTH (1-39) 5 mg · PEG-MGF 2 mg · SLU-PP-332 5 mg · Bacteriostatic Water 3 ml

MGF

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about MGF

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

MGF factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Mechanical Signals, IGF-I Gene Splicing, and Muscle Adaptation

Expression of IGF-1 Isoforms after Exercise-induced Muscle Damage in Humans: Characterization of the MGF E Peptide Actions In Vitro

Mechano-growth Factor Reduces Loss of Cardiac Function in Acute Myocardial Infarction

Mechano Growth Factor E Peptide (MGF-E), Derived from an Isoform of IGF-1, Activates Human Muscle Progenitor Cells and Induces an Increase in Their Fusion Potential at Different Ages

Mechano-growth Factor Peptide, the COOH Terminus of Unprocessed Insulin-like Growth Factor 1, Has No Apparent Effect on Myoblasts or Primary Muscle Stem Cells

Insulin-Like Growth Factor I (IGF-1) Ec/Mechano Growth Factor – A Splice Variant of IGF-1 within the Growth Plate

Mechano-Growth Factor: An Important Cog or a Loose Screw in the Repair Machinery?

The Prohibited List (2026) — S2.3 Growth Factors and Growth Factor Modulators

Questions buyers ask about MGF

Compare adjacent molecules and documentation needs.

PEG-MGF

IGF-1 LR3

Sermorelin

GHRP-2